BNA™ technology opens a window of opportunity for the management of a wide range of brain disorders.
The BNA™ Analysis System is cleared for marketing in the United States by the US Food & Drug Administration (FDA).
elminda has outlined its development plan for the upcoming years, focusing on applications that present the most prominent unmet market needs, and where the company’s technology has the most potential benefit. Research programs include the following: mTBI (concussion) recovery management, pharmacologic treatment optimisation, ADHD diagnosis and treatment optimisation, pain management, early detection of neurodegenerative diseases, and mood disorders.
The company is also leading a multi-year government funded research program for the development of BNA™ guided closed-loop neuro-modulation treatment technology.